Upper urinary tract urothelial carcinoma (UTUC) arises from the renal pelvicalyceal system and ureters and accounts for 5–10% of all urothelial carcinomas. After definitive UTUC treatment by radical nephroureterectomy with bladder cuff excision (RNU), 25-45% of the patients develop intravesical recurrences (IVR). Management of these recurrences is primarily extrapolated from primary bladder cancer (PBC) treatment guidelines.